IM-UNITI efficacy assessments a at week 92 among randomised patients entering LTE
| Continuous 90 mg UST Q12 wks n=84 | Continuous 90 mg UST Q8wks n=82 | Subjects with Prior dose-adjustment
b
n=71 | All Ustekinumab treated n=237 | |
|---|---|---|---|---|
| Clinical Remission (%) | 72.6 | 74.4 | 53.5 | 67.5 |
| Clinical Response (%) | 83.3 | 80.5 | 67.6 | 77.6 |
| Clinical Remission and not receiving corticosteroids at Week 92 (%) | 67.9 | 63.4 | 42.3 | 58.6 |
| Clinical Remission in patients refractory or intolerant to TNF-antagonists | 19/32 (59.4%) | 19/27 (70.4%) | 15/32 (46.9%) | 53/91 (58.2%) |
| Clinical Remission in patients naïve to TNF-antagonists | 29/38 (76.3%) | 29/39 (74.4%) | 18/28 (64.3%) | 76/105 (72.4%) |
| Median change in CDAI from maintenance baseline | −34.0 | −40.0 | −24.0 | −36.0 |